NeuroTherapeutics raises $43 million series B with strong pharma backing
This article was originally published in Scrip
NeuroTherapeutics Pharma has attracted funding from Pfizer and GlaxoSmithKline's corporate venture arm in its latest investment round. The Chicago, Illinois-based firm raised $43 million in a series B financing that included new investors Fidelity Biosciences, MPM Capital and SR One (GSK's venture arm), which co-led the transaction, and Pfizer. Existing investors Novo Ventures and Thomas McNerney & Partners also participated.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.